I N T R O D U C T I O N
Rare diseases are life-threatening or chronically debilitating diseases that are of such low prevalence that special efforts are needed to address them [1] . The definition of a rare disease generally used in Europe is based on a prevalence of less than 1 in 2000 people. According to this definition, there are ∼5000-7000 rare diseases affecting 6-8% of the population and, therefore, between 27 and 36 million people are suffering from a rare disease in Europe alone [1] .
More than 80% of rare diseases have a genetic cause and are present throughout patient's lifetime. The age at first presentation may vary widely and diseases relatively common in children may be rare in adults and vice versa. In addition, ethnicity and environmental factors might influence the prevalence distribution of individual diseases in different parts of the world.
Recently, international initiatives have been launched to better address the health needs of patients with rare diseases. Orphanet, a reference portal for information on rare diseases and orphan drugs, offers an inventory of rare diseases, including a classification system and information on the causative genes, as well as an inventory of orphan drugs in all stages of development. To date, the Orphanet classification system comprises >6700 rare diseases [2] .
The overall prevalence of renal replacement therapy (RRT) in the European population is ∼1000 per million population (pmp) [3] . Hence, end-stage renal disease (ESRD) is not a rare condition. However, some of the underlying conditions that lead to ESRD are considered to be rare.
The aims of this study were to (i) identify those rare diseases within the ERA-EDTA Registry for which RRT is being provided and (ii) to determine the prevalence and incidence of RRT for these rare diseases, both overall and separately for children and adults.
M AT E R I A L S A N D M E T H O D S

Patient population
Data on the incidence and prevalence of RRT were extracted from the ERA-EDTA Registry including information on both children and adults from 12 countries with 165 million European residents.
Data from the following registries were included: Austria, Denmark, Andalusia (Spain), Asturias (Spain), Basque Country (Spain), Canary Islands (Spain), Castile and Leon (Spain), Castile-La Mancha (Spain), Catalonia (Spain), Extremadura (Spain), Galicia (Spain), Valencian region (Spain), Finland, France (from 2008 onwards with increasing geographical coverage), Greece, Iceland, the Netherlands, Norway, Romania, Sweden and Scotland (UK).
All patients younger than 20 years were assessed in the paediatric age group, whereas those 20 years and older were included in the adult group.
Disease coding
Searching the ORPHANET classification tables for rare diseases [4] , 31 Orphanet diagnoses could be identified as rare diseases potentially causing ESRD. The Orphanet codes and corresponding ERA-EDTA primary renal disease (PRD) codes [3] are summarized in Table 1 . If available, the prevalence data for the general population according to Orphanet were added [2] .
For the following disease entities, either Orphanet disease codes or ERA-EDTA PRD codes were grouped to allow for mapping: congenital renal hypo-or dysplasia, prune belly syndrome and reflux nephropathy or obstructive uropathies were summarized in one single category named congenital anomalies of the kidney and urinary tract (CAKUT; ORPHA numbers: 1848, 93173, 97362 and 2970, including PRDs 21, 22, 24, 60, 63 and 66). There is some uncertainty regarding subcategories of CAKUT being a rare disease as some of the ERA-EDTA PRD codes for CAKUT do not exactly match those of Orphanet. However, although the prevalence in the general population is unknown, it is likely to be very low.
Familial renal amyloidosis, primary and secondary amyloidosis, and familial Mediterranean fever (ORPHA numbers 342, 69, 85445 and 85450) were combined as amyloid (PRD code 83). The PRDs for focal segmental glomerulosclerosis (FSGS) in children and adults (PRDs 11 and 17) were also combined (ORPHA numbers 93213 and 93218), and those of autosomal recessive and dominant medullary cystic kidney disease (ORPHA numbers 731 and 655) were merged into medullary cystic kidney disease (PRD code 43). Familial and non-familial renal cell carcinoma as well as WAGR and Denys-Drash Syndrome (ORPHA numbers 151, 217071, 893 and 220) were grouped as kidney tumour (PRD 95).
Statistical procedures
Incidence was defined as the number of patients starting RRT in the 5-year period from 2007 to 2011. The point prevalence was defined as the total number of patients on RRT on 31 December 2011. Both incidence and prevalence were expressed as absolute numbers, pmp and per million age-related population ( pmarp). The size of the related general population was derived from Eurostat, the national bureaus of statistics and the contributing national or regional registries.
All statistical analyses were performed using SAS 9.2 software (SAS Institute, Inc. Cary, NC, USA).
R E S U LT S
From 1 January 2007 to 31 December 2011, 100 745 patients included in the contributing registries in Europe started RRT. Of those, 1491 (1.5%) patients were younger than 20 years of age. The incidence of RRT was 135.2 pmp in the total population, 8.9 pmarp in children and 171.7 pmarp in adults ( Table 2) .
Of the 100 745 patients, 7194 (7.1%) began RRT for a rare disease. The rare disease entities showing the highest overall incidence were CAKUT (2.26 pmp for all patients, 2.49 pmarp in children and 2.20 pmarp in adults) and FSGS (2.09 pmp for all patients, 0.68 pmarp in children and 2.51 pmarp in adults). For all other rare diseases associated with ESRD, the incidence was <1 pmp Children and adolescents were 10.6% of the patients initiating RRT for a rare disease. Twenty-eight per cent of the paediatric RRT population started RRT for CAKUT. Other relatively common diseases in children were FSGS (7.6%), medullary cystic kidney disease (3.5%), haemolytic uraemic syndrome (HUS; 2.7%) and autosomal recessive (infantile) polycystic kidney disease (ARPKD; 2.1%). In contrast, only FSGS (1.5%) and CAKUT (1.3%) contributed >1% to the spectrum of renal diseases for which RRT was provided in adults.
While, for some diseases, RRT was exclusively started in adults (cryoglobulinaemic glomerulonephritis, Fabry disease, systemic sclerosis and tuberculosis), primary oxalosis, cystinosis, CAKUT and medullary cystic kidney disease (nephronophthisis) required RRT in a high percentage (25-46%) of young patients.
The prevalence of RRT is presented in Table 3 . In 2011, the total prevalence of RRT was 165 515 cases (2 063 children and 163 452 adults), corresponding to 1007.6 pmp (56.3 pmarp in children and adolescents and 1280.7 pmarp in adults). Of those 165 515 patients, 20 595 (12.4%) were on RRT for ESRD caused by a rare disease. 
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The prevalence of RRT for rare diseases was 125.4 pmp (32.5 pmarp in children and 152.0 pmarp in adults). Only 5.8% of these patients were younger than 20 years of age. In contrast, 57.7% of all children on RRT had a rare disease as underlying condition, compared with 11.9% of their adult counterparts.
Overall, 46.3 cases pmp were on RRT as a consequence of CAKUT (17.9 pmarp in children and 54.5 pmarp in adults) and 23.5 cases pmp due to FSGS (4.6 pmarp in children and 29.0 pmarp in adults).
In the paediatric age group, CAKUT was the rare disease entity with the highest prevalence of RRT (31.7% of all diagnoses in children on RRT), followed by FSGS (8.2%), medullary cystic kidney disease (4.1%), HUS (3.9%) and ARPKD (3.0%). CAKUT was also the most prevalent diagnosis in adults (4.3% of all diagnoses in adults on RRT), followed by FSGS (2.3%).
Age at first manifestation of a rare disease and age at onset of RRT for ESRD caused by the rare disease may vary widely. Figure 1 displays the age distribution at the initiation of RRT in patients with a rare disease. Among the patients with primary oxalosis, medullary cystic disease, cystinosis or CAKUT who required RRT at some point in their life, more than half of them started RRT before their 40th birthday. On the other hand, in conditions classically considered 'childhood diseases', a substantial fraction of patients started RRT at advanced age (e.g. in cystinosis and ARPKD).
D I S C U S S I O N
Many rare diseases affect the kidneys. Some of these disorders are fairly well known to nephrologists since they typically lead to ESRD in adults, for example, Alport's syndrome. Others causing ESRD in infancy, such as genetic forms of nephrotic syndrome, metabolic diseases and various syndromic disorders of very low prevalence, are generally less well known. Recent epidemiological information on the need for RRT and patient outcome has been provided for selected rare diseases, such as primary oxalosis [5] , cystinosis [6] , Fabry disease [7, 8] and CAKUT [9] , based on analyses of the ERA-EDTA Registry and its paediatric counterpart, the ESPN/ERA-EDTA Registry, as well as other national and international databases. However, information on the overall prevalence of rare diseases within the RRT population is limited or outdated [10] [11] [12] [13] [14] .
To evaluate the contribution of rare diseases to RRT in the European population, we mapped the Orphanet rare disease codes to the ERA-EDTA PRD codes. Twenty-seven of the 62 ERA-EDTA PRD codes, representing 20 disease entities, could be assigned to rare diseases. Accordingly, 12.4% of all the RRT patients would be suffering from a rare disease.
Rare diseases contributed 11.9% to the prevalence of RRT in the adult population. Most diseases requiring RRT in adulthood are common, such as diabetic nephropathy, hypertensive renal vascular disease, autosomal dominant polycystic kidney disease (ADPKD) and IgA nephropathy, accounting for 4 of 10 adult patients on RRT. In contrast, in the paediatric population, rare diseases were identified in nearly 6 of 10 cases. The rare disease entities causing RRT in children and adolescents most frequently were CAKUT, FSGS, medullary cystic kidney disease and HUS. The common diseases listed above accounted for only 4.3% of paediatric RRT cases.
However, the number of patients suffering from rare diseases is most likely an underestimation both for paediatric and adult patients on RRT, since many rare disorders cannot be classified within the current ERA-EDTA PRD coding system. For example, the code 'hereditary nephropathy' includes, among others, patients with congenital nephrotic syndrome. Moreover, 24% of the paediatric patients and 38% of the adult patients had an unspecified or unknown diagnosis, which in many cases may represent an undiagnosed rare disease.
The reported numbers of RRT patients with rare diseases affecting the kidney were collected from 1799 centres contributing to the ERA-EDTA Registry. Considering this figure, the actual prevalence of care is 1 patient with ARPKD per 5 RRT centres, 1 cystinosis patient per 13 centres, 1 patient with primary oxalosis per 21 centres and 1 patient with Fabry disease per 27 centres. Hence, although rare disease patients account for a considerable proportion of the RRT population, individual nephrology centres have a low likelihood of encountering patients with individual rare diseases. This highlights the importance of developing systematic diagnostic and management pathways for this highly heterogeneous population. Such routines should include screening algorithms for patients with unknown cause of chronic kidney disease, which may involve biochemical, imaging and genetic studies as well as kidney biopsy depending on the phenotype. Also, the implementation of reference centres for rare kidney diseases as part of the National Rare Disease Action Plans requested by the EU Commission [1] could facilitate the timely diagnosis and state-of-art management of such disorders both in children and in adults. Establishing transition F I G U R E 1 : Age distribution at onset of RRT. The boxes denote the 25th centile at their right margin, the median and the 75th centile at their left margin; error bars denote the 5th and 95th centile and dots outliers. GN, glomerulonephritis; RVD, renal vascular disease; dense deposit disease, membranoproliferative glomerulonephritis Type II; systemic sclerosis, systemic sclerosis (scleroderma); MPGN, membranoproliferative glomerulonephritis; FSGS, focal segmental glomerulosclerosis; ARPKD, autosomal recessive (infantile) polycystic kidney disease; Alport's syndrome, hereditary nephritis with nerve deafness (Alport's syndrome); CAKUT, congenital anomalies of the kidneys and the urinary tract; medullary cystic disease, medullary cystic disease incl. nephronophthisis; RRT, renal replacement therapy. models between paediatric and adult centres and networking between referring and reference centres will additionally lead to improved patient care. Furthermore, this will enhance opportunities for patient oriented research in the ESRD population.
The potential for identifying more rare disease cases in the RRT population may be substantial in view of the 38% of adults and 24% of children without a specific diagnosis. In these cases, the diagnosis is missing or is currently coded as 'chronic renal failure, aetiology uncertain', 'other identified renal disorders' or glomerulopathies or nephropathies 'due to other causes' or 'unspecified'.
Apart from the potentially large number of undiagnosed cases, the insufficiency of the current classification systems is another major obstacle to the identification of patients with rare kidney diseases. The Orphanet rare disease database contains >6700 rare disease codes [2] . The current 10th version of the International Classification of Diseases (ICD10) [15] comprises only 250 different terms to match these rare disease entities. The currently used ERA-EDTA PRD coding system, which dates back to the 1970s, altogether provides only 65 diagnoses related to ESRD [3] and does not take into account genetic information. The use of this coding system in the ERA-EDTA and ESPN/ERA-EDTA registries obviously represents a major limitation to rare kidney disease research in general and to the analysis presented here in particular. This relates both to the lack of appropriate disease codes and to the inadequate specificity of the available terms. For instance, the observed age distribution at RRT initiation in FSGS patients from early infancy to old age is most likely explained by the admixture of patients with genetic and secondary forms of FSGS, for both of which appropriate disease codes are not available. The same problem applies to the code for 'kidney tumour', which does not allow us to distinguish nephroblastoma in children from renal carcinoma in the elderly. Likewise, the term 'HUS' does not allow the differentiation between the classical Shiga toxin-induced HUS, an infection-related disorder, from atypical HUS, a complementmediated disease caused by genetic predisposition. Whereas classical HUS does not recur, atypical HUS is characterized by a high rate of recurrence in renal allografts and extrarenal complications. The inability to differentiate between these disease entities leads to significant confounding in registry outcome studies.
The correct classification of a disease entity requires a combination of clinical, histopathological and, in a rapidly increasing number of disorders, genetic information. Recently, the ERA-EDTA and the International Health Terminology Standards Development Organization (IHTSDO) have agreed on a comprehensive list of diagnostic codes for kidney disorders reflecting the current state of knowledge regarding aetiology and pathophysiology of the various diseases, which are fully mapped to SNOMED clinical terms [16, 17] . Comprising 273 different renal disease codes, the new system will provide far more detail, making it possible to assign specific and accurate codes to most patients suffering from a rare disease. In parallel, the WHO is working on a new version of the ICD coding system (ICD-11) that will integrate different nosological approaches, including advanced clinical phenotyping, genetic and histopathological classification as well as morbidity grading [18] . These innovations will not only greatly facilitate the classification of rare kidney diseases, but also increase the number of rare conditions. Clinical databases like the ERA-EDTA Registry offer a unique chance to obtain data on certain conditions in specific patient groups or in the general population. In the present analysis, we were able to provide essential information on the prevalence and incidence of defined rare diseases leading to RRT in Europe. However, data quality depends on the tools provided for data collection and on the completeness and volume of data available. Aiming for a high coverage of the population usually results in limited information on details. The outdated disease coding system and apparently often incomplete diagnostic workup were major obstacles to our effort of analysing the contribution of rare diseases to ESRD in Europe. Also, we were unable to derive detailed information on current transition or referral models in patients with rare diseases on RRT from the ERA-EDTA Registry.
In conclusion, at least three of five children and one of nine adults undergoing RRT suffer from ESRD due to rare diseases, with many cases likely to be undiagnosed or miscoded. Comprehensive diagnostic assessment and the application of recently developed, more accurate disease classification systems will be the cornerstone for an improved diagnosis and management of patients with rare kidney diseases.
